Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733729 | 0.89 | LMNA (0.39) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6730176 | 0.85 | PTGS2 (0.42) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6736816 | 0.84 | MEN1 (0.36) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6729762 | 0.84 | LMNA (0.52) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6739661 | 0.84 | CA1 (0.34) | CA2CA1CA4CA7PTGS2 | |
| SCHEMBL6731267 | 0.83 | LMNA (0.38) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6739932 | 0.82 | CA4 (0.34) | CA2CA1CA4CA7PTGS2 | |
| SCHEMBL6738916 | 0.82 | MEN1 (0.37) | MEN1LMNAHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL6737330 | 0.79 | PTGS2 (0.41) | LMNACA2CA1CA4CA7 | |
| SCHEMBL6736778 | 0.79 | MEN1 (0.38) | MEN1LMNAHSP90AA1HSP90AB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | claimed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | claimed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | claimed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | claimed |
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-6699884-B2 | ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. | PHARMACIA CORPORATION | 2004-03-02 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | MEN1 4322/4885LMNA 2247/4885HSP90AA1 1089/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | MEN1 4322/4885LMNA 2247/4885HSP90AA1 1089/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | MEN1 4322/4885LMNA 2247/4885HSP90AA1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.